Influenza Vaccination, ACEI and ARB in the Evolution of SARS-CoV2 Infection

Some authors have proposed the use of the flu vaccine to reduce the severity of COVID-19 cases, while some have proposed the use of ACE Inhibitors (ACEI) or Angiotensin Receptor blockers (ARB), since this virus shares hemagglutinin as a transmission mechanism and acts on the ACE2 enzyme during infection. Other authors described how none of the elderly patients receiving antihistamines and azythromycin in two nursing homes in Toledo -Spain- during the first wave died or needed hospital admission, even considering that 100% of residents had a positive serological test after that wave. Other authors have described a positive evolution in patients receiving amantadine for their Parkinson's disease. The aim is to evaluate whether the admitted patients who are previously vaccinated or those who were already receiving these treatments showed a better evolution.

NCT Number	NCT04367883
Lead Sponsor	Consorci Sanitari de Terrassa Collaborators: Fundacio d'Investigacio en Atencio Primaria Jordi Gol i Gurina, Institut Català de la Salut
Conditions	COVID19, Influenza Vaccination, ACE Inhibitors, ARB, Antihistamine Allergy, Amantadine
Enrollment	3,000 participants
Start Date	2020-03-01
Primary Completion	2025-01-19 (estimated)
Study Completion	2028-02-24 (estimated)
Updated on ClinicalTrials.gov	2026-03-25